

Special Issue

Novel Progress in Cancer Immunotherapy

Message from the Guest Editor

Immunotherapy revolutioned the cancer treatment landscape with advancing developments in oncoimmunology. However, only a low percentage of patients clinically benefit from immune therapeutic agents. Therefore, there is an urgent need to understand the signaling pathways that regulate the cross-talk between tumor cells and immune cells and the relevant treatment-driven resistance mechanisms. Dissecting these dynamic interactions will allow us to discover new targetable molecules in order to develop therapeutic agents or combination therapies to enhance the anti-tumor immune response. In addition, the identification of novel predictive and prognostic immune biomarkers of cancer progression and immunotherapy response will improve the patients' outcome. The Special Issue "Novel Progress in Cancer Immunotherapy" welcomes research articles and reviews including in vitro and in vivo studies on immune checkpoint inhibitors, anti-cancer vaccines, antibody-based therapies and adoptive cell therapies to widely explore the rapidly moving field of immunotherapy.

Guest Editor

Dr. Sheila Spada

Regina Elena National Cancer Institute, Hospital Physiotherapy Institutes (IRCCS), Rome, Italy

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/187315

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).